MedPath

An efficacy, safety and pharmacokinetic study on the short-term and long-term use of METFORMIN in obese children and adolescents

Conditions
obese children and adolescents of Caucasian descent with insulin resistance in the age of = 10 and = 16 years at study entry.
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Registration Number
EUCTR2010-023980-17-NL
Lead Sponsor
St. Antonius Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

The inclusion criteria are subject’s age = 10 and = 16 years at study entry, from Caucasian descent, with obesity defined as BMI-SDS > 2.3 and with insulin resistance defined as HOMA-IR = 3.4. In addition an obtained informed consent from subjects and parents/caregivers.

Are the trial subjects under 18? yes
Number of subjects for this age range: 144
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

The exclusion criteria are presence of T2DM (American Diabetes Association criteria); presence of endocrine disorders with steroid therapy; suspicion of polycystic ovarium syndrome; height < -1.3 SD of target height; syndrome disorders with or without mental retardation; use of anti-hyperglycaemic drugs; pregnancy (pregnancy test will be performed, if applicable); (history of) alcohol abuse; impaired renal and/or hepatic function (defined as GFR < 80 ml/min. GFR= 40 x length (cm) / serumcreatinin (µmol/l), and ALAT >150% of normal value for age); use of ritonavir; use of ACE inhibitors; insufficient knowledge of the Dutch language.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath